Trials / Completed
CompletedNCT04457479
APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 190 (actual)
- Sponsor
- Acandis GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up study to collect comprehensive information on technical and clinical success and safety of the use of APERIO® Hybrid(17/21) Thrombectomy Device in clinical practice. APERIO® Hybrid(17/21) Thrombectomy Device will be used within its approved indication.
Detailed description
German APERIO® Hybrid Post- Market Clinical Follow-up Study APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke Study Type: prospective, multicenter, single-armed, open-label Participants: 8 participating centers in Germany PI: Dr. Christian Mathys, Evangelisches Krankenhaus Oldenburg, Germany Estimated Enrolment: 190 patients treated with APERIO® HYBRID(17/21) Thrombectomy Device as a result of an acute stroke Follow up: 3 months Estimated Final Assessment: Mid to End of 2023
Conditions
Timeline
- Start date
- 2020-11-02
- Primary completion
- 2023-01-16
- Completion
- 2023-06-30
- First posted
- 2020-07-07
- Last updated
- 2023-08-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04457479. Inclusion in this directory is not an endorsement.